Chemotherapy-Induced Emesis in Elderly Cancer Patients: The Role of 5-HT₃-Receptor Antagonists in the First 24 Hours

By  

Gerontology, Vol. 51, Iss. 5, 2005-08 ,pp. : 287-296

Karger

Access to resources Recommend Favorite

Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT₃ receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States

By Schwartzberg Lee   Morrow Gary   Balu Sanjeev   Craver Chris   Gayle Julie   Cox David  

Current Medical Research and Opinion, Vol. 27, Iss. 8, 2011-08 ,pp. : 1613-1622

Informa Healthcare

Access to resources Recommend Favorite

Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy‐induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 10, 2015-10 ,pp. : 911-914

John Wiley & Sons Inc

Access to resources Recommend Favorite

Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy‐induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 919-8172, Iss. 10, 2015-10 ,pp. : 911-914

John Wiley & Sons Inc

Access to resources Recommend Favorite

Chemotherapy-Induced Nausea and Vomiting in the Treatment of Gastrointestinal Tumors and Secondary Prophylaxis with Aprepitant

By  

Oncology Research and Treatment, Vol. 32, Iss. 1-2, 2009-01 ,pp. : 30-34

Karger

Access to resources Recommend Favorite